Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

Literature DB >> 11450667

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

J A Ledermann, P Leonard, M Seymour.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2001 PMID： 11450667

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

1. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer.

Authors: Michael S Braun; Matthew T Seymour
Journal: Ther Adv Med Oncol Date: 2011-01 Impact factor: 8.168

2. Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.

Authors: Sang Joon Shin; Jae Heon Jeong; Young Suk Park; Kyung Hee Lee; Byoung Yong Shim; Tae Won Kim; Do Youn Oh; Myung Ah Lee; Yong Tai Kim; Yeul Hong Kim; Dae Young Zang; Jae Kyung Roh; Joong Bae Ahn
Journal: Invest New Drugs Date: 2010-03-21 Impact factor: 3.850

3. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.

Authors: P Leonard; M T Seymour; R James; D Hochhauser; J A Ledermann
Journal: Br J Cancer Date: 2002-11-18 Impact factor: 7.640

4. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

Authors: J Feliu; C Castañón; A Salud; J R Mel; P Escudero; A Pelegrín; L López-Gómez; M Ruiz; E González; F Juárez; J Lizón; J Castro; M González-Barón
Journal: Br J Cancer Date: 2005-11-28 Impact factor: 7.640

5. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.

Authors: Andreas Teufel; Silke Steinmann; Jürgen Siebler; Christiane Zanke; Herbert Hohl; Bernd Adami; M Schroeder; O Klein; Thomas Höhler; Peter R Galle; Michael Heike; Markus Moehler
Journal: BMC Cancer Date: 2004-07-20 Impact factor: 4.430

Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

1. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer.

2. Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer.

3. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.

4. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

5. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.

6. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.

7. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.

8. Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.

9. Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.

10. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.